Exelixis, Inc. (EXEL)

Market Cap	11.13B +9.4%
Revenue (ttm)	2.29B +9.9%
Net Income	677.90M +45.2%
EPS	2.38 +53.5%
Shares Out	269.20M
PE Ratio	17.40
Forward PE	13.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,436,169
Open	42.18
Previous Close	42.28
Day's Range	40.76 - 42.50
52-Week Range	32.38 - 49.62
Beta	0.40
Analysts	Buy
Price Target	46.05 (+11.34%)
Earnings Date	Feb 10, 2026

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,147
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Analyst Summary

According to 22 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $46.05, which is an increase of 11.34% from the latest price.

Price Target

$46.05

(11.34% upside)

Analyst Consensus: Buy